Lecanemab Extension Study for AD Offers Mixed Results
The lecanemab open-label extension trial for AD showed no new safety signals, but the placebo roll-over group failed to show the gains seen in the experimental arm.
Source: medscape.com
Eisai Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Eisai Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Eisai Ltd Today - Breaking & Trending Today
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines - Biogen (NASDAQ:BIIB)
Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval.
Source: benzinga.com
Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial - Merck & Co (NYSE:MRK), Eisai Co (OTC:ESALF)
Merck & Co Inc (NYSE: MRK) and Eisai Ltd (OTC: ESALY) provided an update on the Phase 3 LEAP-010 trial evaluating Keytruda (pembrolizumab), plus Lenvima for recurrent or metastatic head and neck squamous c
Source: benzinga.com
Spectrum of CV Effects of Immune Checkpoint Inhibitors Defined
They take a range of forms and are an increasingly common clinical issue with the growing list of cancers for which the immunologic agents are indicated.
Source: medscape.com
New leaders for Swiss tech startups Startupticker.ch | The Swiss Startup News channel
The Zurich-based startup offering a forecasting tool for the foodservice industry has made changes in its leadership. Former CTO Roman Lickel is now the company’s Managing Director. Roman takes over the role from Simon Michel, with whom he built Prognolite. “The last few years have been an incredibly intense and beautiful time. Although I believe in success more than ever, I see that Prognolite can be better led by my co-founder Roman together with Nico with the somewhat changed focus. As a shareholder, however, I will remain closely connected to Prognolite,” says Simon. For its platf...
Source: startupticker.ch